poisar

Stocks · News reference

Ionis Pharmaceuticals Presents New Long-Term Data for DAWNZERA® at ACAAI 2026

Fiscal.ai

Ionis Pharmaceuticals announced new long-term efficacy and safety data for its RNA-targeted hereditary angioedema (HAE) medicine, DAWNZERA® (donidalorsen), at the 2026 ACAAI Annual Scientific Meeting.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading